Ropivacaine, a local anesthetic, has been shown to inhibit HIF-1α signaling in lung cancer cells, along with downstream VEGF signaling, thus reducing angiogenesis in malignant lung cancers (62). The gene discussed is HIF1A; the disease is lung cancer.